Next Article in Journal
Identification of Light-Independent Anthocyanin Biosynthesis Mutants Induced by Ethyl Methane Sulfonate in Turnip “Tsuda” (Brassica rapa)
Next Article in Special Issue
Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits
Previous Article in Journal
Adolescent Exposure to the Synthetic Cannabinoid WIN 55212-2 Modifies Cocaine Withdrawal Symptoms in Adult Mice
Previous Article in Special Issue
Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes
Open AccessReview

Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies

Metabolic Signalling Group, School of Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, WA 6102, Australia
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2017, 18(7), 1338; https://doi.org/10.3390/ijms18071338
Received: 21 March 2017 / Revised: 1 June 2017 / Accepted: 13 June 2017 / Published: 22 June 2017
(This article belongs to the Special Issue Pancreatic Disorders)
Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is the fourth leading cause of cancer-related deaths in the world. Due to the broad heterogeneity of genetic mutations and dense stromal environment, PDAC belongs to one of the most chemoresistant cancers. Most of the available treatments are palliative, with the objective of relieving disease-related symptoms and prolonging survival. Currently, available therapeutic options are surgery, radiation, chemotherapy, immunotherapy, and use of targeted drugs. However, thus far, therapies targeting cancer-associated molecular pathways have not given satisfactory results; this is due in part to the rapid upregulation of compensatory alternative pathways as well as dense desmoplastic reaction. In this review, we summarize currently available therapies and clinical trials, directed towards a plethora of pathways and components dysregulated during PDAC carcinogenesis. Emerging trends towards targeted therapies as the most promising approach will also be discussed. View Full-Text
Keywords: PDAC; chemotherapy; gemcitabine; Abraxane; FOLFIRINOX; combination therapies; targeted therapies PDAC; chemotherapy; gemcitabine; Abraxane; FOLFIRINOX; combination therapies; targeted therapies
Show Figures

Figure 1

MDPI and ACS Style

Adamska, A.; Domenichini, A.; Falasca, M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int. J. Mol. Sci. 2017, 18, 1338. https://doi.org/10.3390/ijms18071338

AMA Style

Adamska A, Domenichini A, Falasca M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. International Journal of Molecular Sciences. 2017; 18(7):1338. https://doi.org/10.3390/ijms18071338

Chicago/Turabian Style

Adamska, Aleksandra; Domenichini, Alice; Falasca, Marco. 2017. "Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies" Int. J. Mol. Sci. 18, no. 7: 1338. https://doi.org/10.3390/ijms18071338

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop